Physician profile
Gary R Rylander
NPI 1205831344
$1,418.68
in general payments reported to CMS, 2019-2025
20 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $198 · 2022: $218 · 2023: $276 · 2024: $297 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $553.84 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Aerie Pharmaceuticals, INC. | $141.51 | 2020 | |
| Harrow Eye, LLC | $128.14 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $92.52 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $84.26 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $72.61 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $59.73 | 2019-2020 | |
| Amgen INC. | $46.13 | 2024-2025 | Tepezza |
| Shire North American Group INC | $27.88 | 2019 | |
| Alcon Vision LLC | $26.56 | 2022-2024 | Rocklatan |
| Sun Pharmaceutical Industries INC. | $26.23 | 2023 | Cequa |
| Mallinckrodt Hospital Products INC. | $24.69 | 2020 | |
| Oyster Point Pharma, INC. | $24.35 | 2022 | |
| Dompe US, INC. | $22.77 | 2022 | |
| Rayner Intraocular Lenses Limited | $21.77 | 2023 | Rayone Emv, Omidria, Rayone Aspheric |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $21.45 | 2019 | |
| Tearlab Corp | $15.35 | 2022 | |
| Thea Pharma INC. | $13.99 | 2022 | |
| Ocular Therapeutix, INC. | $13.53 | 2020 | |
| Visioneering Technologies, INC. | $1.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Rylander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.